HuGE Literature Finder
Records 1-15
|
Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients.
Breast cancer research : BCR 2021 Mar 23 (1): 31. Darrigues Lauren, Pierga Jean-Yves, Bernard-Tessier Alice, Bièche Ivan, Silveira Amanda Bartolini, Michel Marc, Loirat Delphine, Cottu Paul, Cabel Luc, Dubot Coraline, Geiss Romain, Ricci Francesco, Vincent-Salomon Anne, Proudhon Charlotte, Bidard François-Cléme |
|
Significant impact of circulating tumour DNA mutations on survival in metastatic breast cancer patients.
Scientific reports 2021 Mar 11 (1): 6761. Muendlein Axel, Geiger Kathrin, Gaenger Stella, Dechow Tobias, Nonnenbroich Christoph, Leiherer Andreas, Drexel Heinz, Gaumann Andreas, Jagla Wolfgang, Winder Thomas, Mayer Frank, Decker Thom |
|
Limited Practical Utility of Liquid Biopsy in the Treated Patients with Advanced Breast Cancer.
Diagnostics (Basel, Switzerland) 2020 Jul 10 (8): . Niwinska Anna, Balabas Aneta, Kulecka Maria, Kluska Anna, Piatkowska Magdalena, Paziewska Agnieszka, Pysniak Kazimiera, Olszewski Wojciech, Mikula Michal, Ostrowski Jer |
|
Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance.
Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Oct . Pearson Alex, Proszek Paula Z, Pascual Javier, Fribbens Charlotte, Shamsher Monee K, Kingston Belinda, O'Leary Ben, Herrera-Abreu Maria Teresa, Cutts Rosalind J, Garcia-Murillas Isaac, Bye Hannah, Walker Brian A, Gonzalez De Castro David, Yuan Lina, Jamal Sabri, Hubank Michael, López-Knowles Elena, Schuster Eugene F, Dowsett Mitch, Osin Peter, Nerurkar Ashutosh, Parton Marina, Okines Alicia Fc, Johnston Stephen R D, Ring Alistair, Turner Nicholas |
|
CDK4/6 Inhibitors in Combination With Hormone Therapy for HR/HER2 Advanced Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Clinical breast cancer 2018 May . Deng Yunfu, Ma Guangzhi, Li Wen, Wang Ting, Zhao Yaqin, Wu Qia |
|
Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers.
Clinical cancer research : an official journal of the American Association for Cancer Research 2018 May . Anurag Meenakshi, Punturi Nindo, Hoog Jeremy, Bainbridge Matthew N, Ellis Matthew J, Haricharan Svas |
|
Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole.
Oncotarget 2017 Sep 8 (40): 66901-66911. Gyanchandani Rekha, Kota Karthik J, Jonnalagadda Amruth R, Minteer Tanya, Knapick Beth A, Oesterreich Steffi, Brufsky Adam M, Lee Adrian V, Puhalla Shannon |
|
A gene expression signature of retinoblastoma loss-of-function is a predictive biomarker of resistance to palbociclib in breast cancer cell lines and is prognostic in patients with ER positive early breast cancer.
Oncotarget 2016 Sep 7 (42): 68012-68022. Malorni Luca, Piazza Silvano, Ciani Yari, Guarducci Cristina, Bonechi Martina, Biagioni Chiara, Hart Christopher D, Verardo Roberto, Di Leo Angelo, Migliaccio Ilen |
|
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
The Lancet. Oncology 2016 Mar . Cristofanilli Massimo, Turner Nicholas C, Bondarenko Igor, Ro Jungsil, Im Seock-Ah, Masuda Norikazu, Colleoni Marco, DeMichele Angela, Loi Sherene, Verma Sunil, Iwata Hiroji, Harbeck Nadia, Zhang Ke, Theall Kathy Puyana, Jiang Yuqiu, Bartlett Cynthia Huang, Koehler Maria, Slamon Denn |
|
A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.
The oncologist 2014 May 19 (5): 453-8. Vasan Neil, Yelensky Roman, Wang Kai, Moulder Stacy, Dzimitrowicz Hannah, Avritscher Rony, Wang Baliang, Wu Yun, Cronin Maureen T, Palmer Gary, Symmans W Fraser, Miller Vincent A, Stephens Philip, Pusztai Laj |
|
Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predisposition to uveal melanoma.
Familial cancer 2010 Dec 9 (4): 663-7. Buecher B, Gauthier-Villars M, Desjardins L, Lumbroso-Le Rouic L, Levy C, De Pauw A, Bombled J, Tirapo C, Houdayer C, Bressac-de Paillerets B, Stoppa-Lyonnet |
|
Association of single-nucleotide polymorphisms in the cell cycle genes with breast cancer in the British population.
Carcinogenesis 2008 Feb 29 (2): 333-41. Driver Kristy E, Song Honglin, Lesueur Fabienne, Ahmed Shahana, Barbosa-Morais Nuno L, Tyrer Jonathan P, Ponder Bruce A J, Easton Douglas F, Pharoah Paul D P, Dunning Alison M, |
|
Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1.
Breast cancer research and treatment 2008 Jan 107 (1): 95-102. Yu Cheng-Ping, Yu Jyh-Cherng, Sun Chien-An, Tzao Ching, Ho Jar-Yi, Yen Amy Ming-Fa |
|
Effects of common germline genetic variation in cell cycle control genes on breast cancer survival: results from a population-based cohort.
Breast cancer research : BCR 2008 10 (3): R47. Azzato Elizabeth M, Driver Kristy E, Lesueur Fabienne, Shah Mitul, Greenberg David, Easton Douglas F, Teschendorff Andrew E, Caldas Carlos, Caporaso Neil E, Pharoah Paul D |
|
BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma.
Familial cancer 2007 6 (4): 453-61. Monnerat Christian, Chompret Agnès, Kannengiesser Caroline, Avril Marie-Françoise, Janin Nicolas, Spatz Alain, Guinebretière Jean-Marc, Marian Catalin, Barrois Michel, Boitier Françoise, Lenoir Gilbert M, Bressac-de Paillerets Brigit |
- Page last reviewed:Oct 1, 2020
- Page last updated:Sep 23, 2021
- Content source: